Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study Of CNTY-101 At ASCO 2024 Annual Meeting In patients with Relapsed or Refractory, CD19-Positive B-Cell Malignancies
$IPSC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting.
- Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels.
- Novel cell-free DNA method for detecting total body PK suggests CNTY-101 persists outside the bloodstream.
- Enrollment continues in dose escalation phase of ELiPSE-1 at dose levels 3B (three weekly infusions of 1 billion cells) and 4A (single infusion of 3 billion cells) per cycle.